Skip to main content
TSHA logo

TSHA · Taysha Gene Therapies, Inc.

Track TSHA — free
$3.99 -0.01 (-0.25%) At close · Nov 18
Market Cap
$1.30B
Shares
326.05M
Volume · Nov 18 3.55M Avg daily vol (3M) 3.62M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.99 Open$4.00 Day$3.97–4.22 52W close$3.51–6.98 Avg vol 30d3.6M Short int53.5M · 16.4% of shares · 14.8d Short vol34% Last earningsNov 12, 2026 DataSep 2020–Nov 2026 Filing10-Q · Nov 12

Up next

Dec 31, 2026 Est · unconfirmed · in 6 wks

Latest documents

2026
Nov 12
Earnings call
All 33 patients cleared acute safety monitoring

Tayshia said all 33 patients cleared acute safety monitoring, with no severe treatment-related serious adverse events or dose-limiting toxicities as of the November 2026 cutoff. Six-month interim data and FDA pathway feedback are expected in the first half of 2027.

3 source passages
Following the completion of dosing in both the Reveal Pivotal and Aspire trials, we are pleased to announce that all 33 patients dosed with Tayshia 102, 29 in the Reveal Phase 1-2 and Pivotal trials, and 4 in the Aspire trial have cleared the acute post-dosing safety monitoring period associated with AAV gene therapies. Notably, across the broader... Tayshia 102 clinical program, which began over three years ago, 33 patients spanning a broad range of ages, genotypes, and disease severities have been treated, with no severe treatment-related serious adverse events or dose-limiting toxicities reported as of the November 2026 data cutoff, supporting a favorable and consistent safety profile for trial participants across the program. We continue to expect to report full top-line data from the interim analysis and potential feedback from the FDA on next steps in the BLA submission pathway in the first half of 2027. Open the document at this passage
Nov 12
Current report 8-K
TSHA-102 PPQ campaign completed

Taysha Gene Therapies completed TSHA-102’s BLA-enabling PPQ campaign, meeting predefined specifications and comparability criteria; topline data from the REVEAL pivotal 6-month interim analysis and FDA feedback on the BLA submission pathway are expected in the first half of 2027.

Financial results
4 source passages
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update. Completed BLA-Enabling Process Performance Qualification (PPQ) Campaign for TSHA-102. All process parameters and analytical results met predefined product specifications as well as comparability criteria for commercial product and clinical material. Topline data from the REVEAL pivotal trial 6-month interim analysis and FDA feedback on the BLA submission pathway for TSHA-102 expected in the first half of 2027 Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
TSHA-102 yielded milestone gains in all 12 patients

Taysha Gene Therapies said all 12 REVEAL Part A patients gained or regained at least one developmental milestone after TSHA-102. The 17-patient REVEAL pivotal trial has completed dosing, with topline data expected in the first half of 2027.

Revenue $0 Net loss $39.13M Diluted EPS -$0.10
Read from the MD&A section
3 source passages
As of the May 2026 data cutoff, 100% of the 12 patients in REVEAL Part A gained or regained ≥ one developmental milestone across the core functional domains of fine motor, gross motor and communication post-treatment with TSHA-102. We have completed dosing of the 17 patients aged 6 to <22 years in the overenrolled REVEAL pivotal trial, and enrollment for this trial is complete with a well-balanced age distribution across all pediatric, adolescent and adult patients dosed. We plan to discuss data from the 6-month interim analysis and next steps toward the BLA submission pathway with the FDA, with topline data and regulatory feedback anticipated in the first half of 2027. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$5.49M
Trailing 12 months
Net income (TTM)
−$156.03M
Trailing 12 months
Revenue growth YoY
+17.3%
Year over year
Operating margin
-2,935.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$375.50M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+14.9%
Year over year · more shares
Price change (1Y)
-3.9%
Trailing year
Short interest
16.4%
Latest settlement · 14.8 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −25%
below
Price vs 50-day avg −9%
below
RSI (14) 42
neutral
MACD trend Positive
52-week position 14%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −3%
trailing
6-month return −32%
trailing
YTD return −27%
this year
Relative strength −29%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow Distributing
-1% holders QoQ · +27 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
16.40% of shares out · ▲ +4.3% MoM · 14.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
206 holders — near 3-yr high, broad support
Squeeze score 80
high risk · 0–100
Fundamentals
Strong
Revenue growth +17%
Y/Y
EPS growth +6%
Y/Y
Free cash flow $-93.8M
Balance sheet $269.7M
net cash
Quant / Vol
risk profile
Very High
Volatility 71%
annualized · 1-yr
Max drawdown −50%
past year
ATR 6.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Aug 14, 2023
Private placement gross proceeds · PIPE closing $150M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−25% Bearish
Price vs 50-day avg
−9% Bearish
RSI (14)
42 Neutral
MACD trend
Positive Bullish
52-week position
14% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow Distributing
-1% holders QoQ · +27 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
16.40% of shares out · ▲ +4.3% MoM · 14.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
206 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4 Now $4 · 14% Range high $7
vs 200-day avg -25% vs 50-day avg -9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TSHA
Taysha Gene Therapies, Inc.
this stock
$1.30B -27.5% +17.3% — 16.4%
VRTX
Vertex Pharmaceuticals Inc
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
206
% held
97.1%
Net QoQ
+17.1M sh
Top holder
RA CAPITAL MANAGEMENT, L.…
Held Float
View
Held by Funds
Fund positions
169
View
Short & Settlement
Short Interest Rising
Shares short
53.5M
Days to cover
14.8d
Change
+2.2M sh
View
Short Volume
Short vol %
34%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
337
Value
$1.4K
As of
Oct 22, 2026
View
Off-Exchange
Off-exchange %
44.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$9.8M
Net income (FY)
$-109.0M
EPS diluted
$-0.34
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 12, 2026
This year
17

Taysha Gene Therapies said all 12 REVEAL Part A patients gained or regained at least one developmental milestone after TSHA-102. The 17-patient REVEAL pivotal trial has completed dosing, with topline data expected in the first half of 2027.

View
Proposed Sales
Value
$1.3M
Shares
200.0K
Filed
Jul 10, 2026
View
Exempt Offerings
Offering
$150.0M
Filed
Aug 25, 2023
View
Earnings & Events
Webcasts
Last webcast
Nov 12, 2026
View
Investor Relations
Latest news
Taysha Gene Therapies Reports Thi…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
TSHA -6.8% -3.2% -32.0% -3.4% -27.5%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -2.9% +2.4% -28.6% 0.0% -34.5%
Key facts CIK 1806310 CUSIP 877619106 13F (30d) 217 filings 199 filers Visit website Investor relations